BR112019025164A2 - Esquema de dosagem para tesetaxel e capecitabina - Google Patents
Esquema de dosagem para tesetaxel e capecitabina Download PDFInfo
- Publication number
- BR112019025164A2 BR112019025164A2 BR112019025164-2A BR112019025164A BR112019025164A2 BR 112019025164 A2 BR112019025164 A2 BR 112019025164A2 BR 112019025164 A BR112019025164 A BR 112019025164A BR 112019025164 A2 BR112019025164 A2 BR 112019025164A2
- Authority
- BR
- Brazil
- Prior art keywords
- capecitabine
- tesetaxel
- dosage scheme
- patient
- dosage
- Prior art date
Links
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 title abstract 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004117 capecitabine Drugs 0.000 title abstract 2
- MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 title abstract 2
- 229950009016 tesetaxel Drugs 0.000 title abstract 2
- 206010055113 Breast cancer metastatic Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762514483P | 2017-06-02 | 2017-06-02 | |
| US62/514,483 | 2017-06-02 | ||
| PCT/US2018/035653 WO2018223029A1 (en) | 2017-06-02 | 2018-06-01 | Dosing schedule for tesetaxel and capecitabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019025164A2 true BR112019025164A2 (pt) | 2020-06-16 |
Family
ID=64455637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019025164-2A BR112019025164A2 (pt) | 2017-06-02 | 2018-06-01 | Esquema de dosagem para tesetaxel e capecitabina |
Country Status (14)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019359755A1 (en) * | 2018-10-17 | 2021-05-20 | Odonate Therapeutics, Inc. | Methods of treating CNS tumors with tesetaxel |
| TW202112364A (zh) * | 2019-08-16 | 2021-04-01 | 美商蜻蛉治療股份有限公司 | 投與替司他賽(tesetaxel)與cyp3a4誘導劑之糖皮質素之方法 |
| WO2022177835A1 (en) * | 2021-02-16 | 2022-08-25 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201701880A (zh) * | 2015-04-14 | 2017-01-16 | 莫瑞麥克製藥公司 | 改善持續釋放藥物治療之藥物動力學及治療指數之方法 |
-
2018
- 2018-06-01 EA EA201992852A patent/EA201992852A1/ru unknown
- 2018-06-01 MX MX2019014489A patent/MX2019014489A/es unknown
- 2018-06-01 CA CA3065783A patent/CA3065783A1/en not_active Abandoned
- 2018-06-01 BR BR112019025164-2A patent/BR112019025164A2/pt not_active Application Discontinuation
- 2018-06-01 KR KR1020207000023A patent/KR20200014880A/ko not_active Ceased
- 2018-06-01 WO PCT/US2018/035653 patent/WO2018223029A1/en not_active Ceased
- 2018-06-01 EP EP18808779.5A patent/EP3630091A4/en not_active Withdrawn
- 2018-06-01 MA MA050039A patent/MA50039A/fr unknown
- 2018-06-01 JP JP2020516788A patent/JP2020522568A/ja not_active Withdrawn
- 2018-06-01 CN CN201880041477.0A patent/CN111032035A/zh active Pending
- 2018-06-01 AU AU2018275122A patent/AU2018275122A1/en not_active Abandoned
- 2018-06-01 US US16/617,697 patent/US20200179427A1/en not_active Abandoned
- 2018-06-01 TW TW107119026A patent/TW201902473A/zh unknown
-
2019
- 2019-11-27 IL IL270973A patent/IL270973A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA50039A (fr) | 2020-07-08 |
| JP2020522568A (ja) | 2020-07-30 |
| KR20200014880A (ko) | 2020-02-11 |
| AU2018275122A1 (en) | 2019-12-19 |
| CA3065783A1 (en) | 2018-12-06 |
| MX2019014489A (es) | 2020-08-17 |
| EA201992852A1 (ru) | 2020-03-27 |
| WO2018223029A1 (en) | 2018-12-06 |
| US20200179427A1 (en) | 2020-06-11 |
| CN111032035A (zh) | 2020-04-17 |
| TW201902473A (zh) | 2019-01-16 |
| EP3630091A1 (en) | 2020-04-08 |
| EP3630091A4 (en) | 2021-03-10 |
| IL270973A (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004881A (es) | Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno. | |
| PT3431105T (pt) | Composição medicinal para tratamento de cancro | |
| BR112016024789A2 (pt) | métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe | |
| PH12015502075A1 (en) | Treatment of cataplexy | |
| MX2023012451A (es) | Composiciones para usarse en el tratamiento de una enfermedad autoinmune y cancer. | |
| IL265938A (en) | Lasofoxifene treatment of er+ breast cancer | |
| MX385283B (es) | Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control. | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| BR112019001398A2 (pt) | métodos para tratamento de câncer de próstata | |
| BR112018000776A2 (pt) | métodos para tratamento de câncer usando apilimod | |
| MX379271B (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer. | |
| IN2014MU00303A (cg-RX-API-DMAC7.html) | ||
| MX379622B (es) | Compuestos espirociclicos | |
| MX377528B (es) | Compuestos de platino funcionalizados con monomaleimida para la terapia del cáncer. | |
| PH12017500853B1 (en) | Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases | |
| MX381598B (es) | Combinación farmacéutica que comprende un parvovirus y bevacizumab. | |
| BR112017016333A2 (pt) | compostos anticâncer | |
| MX2019003755A (es) | Regimen de dosificacion de avelumab para el tratamiento de cancer. | |
| MX2019014489A (es) | Programa de dosificacion para tesetaxel y capecitabina. | |
| IL252639A0 (en) | Breast cancer treatment using taxane | |
| PH12017500910A1 (en) | Use of sigma receptor ligands in osteoarthritis | |
| MX2018003459A (es) | Tratamiento con trastuzumab vc-seco-duba de pacientes de cancer refractarios a trastuzumab emtansina. | |
| IN2013MU03118A (cg-RX-API-DMAC7.html) | ||
| EP3706752A4 (en) | COMBINATORY THERAPY FOR ANTI-CANCER TREATMENT | |
| MX2016002307A (es) | Tratamiento para el cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |